anti-BCMA antibody-drug conjugate AMG 224

{
  "id": "MLC-T-ONC-010158",
  "term": "anti-BCMA antibody-drug conjugate AMG 224",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) comprised of an anti-human B-cell maturation antigen (BCMA) immunoglobulin G1 (IgG1) antibody conjugated via the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC), to the cytotoxic maytansine-derivative, DM1, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AMG 224 selectively binds to BCMA expressed on the surface of tumor cells. Upon internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of tumor cells that express BCMA. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF)and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-bcma-antibody-drug-conjugate-amg-224/"
}